Laurent Fischer has bought stock on 6 days since Sep 2019

Laurent Fischer, M.D. is a seasoned physician-executive with over 30 years of experience in biopharmaceutical leadership, currently serving as President, CEO, and Director of Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company focused on ocular and rare diseases. He joined Adverum in June 2020, leading the company through key developments including the advancement of ADVM-022 for wet AMD and diabetic macular edema, culminating in its acquisition by Eli Lilly in October 2025.(

Dr. Fischer holds a Medical Degree and Doctorate in Medicine from the University of Geneva/Geneva Medical School, Switzerland. His career highlights include CEO roles at Tobira Therapeutics (acquired by Allergan for $1.7 billion in 2016), Jennerex Biotherapeutics (acquired by SillaJen in 2013), Ocera Therapeutics, and Auxeris Therapeutics, as well as SVP and Head of Liver Therapeutic Area at Allergan, and earlier positions at Hoffmann-La Roche, DuPont Pharmaceuticals, and others. He serves on boards including Mirum Pharmaceuticals, Lycia Therapeutics, Teal Bio, ATAI Life Sciences, and recently as Chair of Shinobi Therapeutics.(

Written by Perplexity from public sources.